scPharmaceuticals Inc. to Participate in the Maxim Group LLC Late-Stage Advancements in Heart Failure Therapeutics and Management Panel Discussion
scPharmaceuticals Inc. (Nasdaq: SCPH) announced that CEO John Tucker will participate in a panel discussion on heart failure therapeutics on July 14, 2022, at 10:00 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
scPharmaceuticals Inc. (Nasdaq: SCPH) announced that CEO John Tucker will participate in a panel discussion on heart failure therapeutics on July 14, 2022, at 10:00 a.m. ET. The event is hosted by Maxim Group LLC and will be available live on M-Vest. The company is dedicated to developing products that enhance infused therapy delivery, improve patient care, and lower healthcare costs. Their focus includes self-administered IV-strength treatments for heart failure and infectious diseases.
Details
News Market Reaction – SCPH
The recorded move for SCPH in the trading session of this news was +0.58%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BURLINGTON, Mass., July 13, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, announced today that John Tucker, president & chief executive officer, is scheduled to participate in the Late-Stage Advancements in Heart Failure Therapeutics and Management panel discussion, presented by Maxim Group LLC and hosted by M-Vest, on Thursday, July 14th, 2022 at 10:00 a.m. ET.
This conference will be live on M-Vest. Click Here to Reserve your seat.
About scPharmaceuticals
scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.
Katherine Taudvin
scPharmaceuticals Inc., 781-301-6706
ktaudvin@scpharma.com
Investors:
Hans Vitzthum
LifeSci Advisors, 617-430-7578
hans@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.